Journal
HUMAN GENE THERAPY
Volume 20, Issue 3, Pages 267-281Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/hum.2008.173
Keywords
-
Categories
Funding
- Cystic Fibrosis Foundation [RDP R881]
- Will Rogers Memorial Fund (Los Angeles, CA)
- [P01 HL51746]
Ask authors/readers for more resources
Cystic fibrosis is characterized by deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR), a Cl- transporter. The packaging constraints of adeno-associated viral (AAV) vectors preclude delivery of both an active promoter and CFTR cDNA to target cells. We hypothesized that segmental trans-splicing, in which two AAV vectors deliver the 50 and 30 halves of the CFTR cDNA, could mediate splicing of two pre-mRNAs into a full-length, functional CFTR mRNA. Using a segmental trans-splicing 5' donor-3' acceptor pair that split the CFTR cDNA between exons 14a and 14b, cotransfection of donor and acceptor plasmids into CFTR- cells resulted in full-length CFTR message and protein. Microinjection of plasmids into CFTR- cells produced cAMP-activated Cl- conductance. Vectors created with an engineered human serotype, AAV6.2, were used to deliver CFTR donor and acceptor constructs, resulting in full-length CFTR mRNA and protein as well as cAMP-activated Cl- conductance in CFTR- cells, including human CF airway epithelial IB3-1 cells. Thus, segmental trans-splicing can be used with AAV vectors to mediate expression of CFTR, a strategy potentially applicable to individuals with CF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available